Legato Capital Boosts Stake in Harmony Biosciences

Institutional investor increases holdings in pharmaceutical company by over 60%

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Legato Capital Management LLC increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 61.1% during the third quarter, according to a recent SEC filing. Legato Capital now owns 51,415 shares of the company's stock, worth $1.4 million.

Why it matters

Harmony Biosciences is a commercial-stage biopharmaceutical company focused on developing therapies for rare neurological and endocrine diseases. The increase in Legato Capital's stake suggests the institutional investor sees growth potential in the company's pipeline and products.

The details

Legato Capital Management added 19,504 shares of Harmony Biosciences to its portfolio during the third quarter, bringing its total holdings to 51,415 shares. Other institutional investors have also been active in the stock, with Amundi, MIRAE ASSET GLOBAL ETFS HOLDINGS, and UBS Asset Management all increasing or initiating positions in the company over the past year.

  • Legato Capital increased its Harmony Biosciences holdings during the third quarter of 2025.
  • Harmony Biosciences is a commercial-stage company that went public in 2020.

The players

Legato Capital Management LLC

An institutional investment firm that has increased its stake in Harmony Biosciences.

Harmony Biosciences Holdings, Inc.

A commercial-stage biopharmaceutical company focused on developing therapies for rare neurological and endocrine diseases.

Got photos? Submit your photos here. ›

The takeaway

Legato Capital's increased investment in Harmony Biosciences suggests the firm sees strong growth potential in the company's portfolio of rare disease treatments, which could signal positive momentum for the stock going forward.